CROI 2013: MK-1439, a Novel HIV NNRTI, Shows Promise in Early Clinical Trials
- Details
- Category: HIV Treatment
- Published on Wednesday, 06 March 2013 00:00
- Written by Liz Highleyman
A next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI), MK-1439, demonstrated robust antiretroviral activity and good tolerability as monotherapy in a small clinical study, researchers reported yesterday at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) in Atlanta.
CROI 2013: French Studies Look at Telaprevir and Boceprevir for People with HIV/HCV Coinfection
- Details
- Category: Experimental HCV Drugs
- Published on Wednesday, 06 March 2013 00:00
- Written by Liz Highleyman
Adding boceprevir or telaprevir to interferon-based therapy showed promising indications of efficacy and acceptable safety for difficult-to-treat HIV/HCV coinfected prior non-responders in a pair of French studies presented at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) in this week in Atlanta.
CROI 2013: Dually Active Antiretroviral Therapy Protects Against Primary Hepatitis B Infection
- Details
- Category: HBV Treatment
- Published on Wednesday, 06 March 2013 00:00
- Written by Liz Highleyman
Use of antiretroviral therapy (ART) that includes drugs active against both hepatitis B virus (HBV) and HIV reduces the risk that HIV positive people will become infected with HBV -- in effect acting as HBV PrEP -- according to a study presented at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) this week in Atlanta.
CROI 2013: Very Early Antiretroviral Treatment Limits the Size of HIV Reservoir
- Details
- Category: Search for a Cure
- Published on Wednesday, 06 March 2013 00:00
- Written by Keith Alcorn
Very early antiretroviral treatment may limit the size of the HIV reservoir in adults and children, according to studies presented this week at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) in Atlanta. Other research presented at the meeting suggests that too little is known about either the size or the cell types that constitute the HIV reservoir to be confident that early assessments will be a reliable guide to the potential for viral eradication.
CROI 2013: Pipeline Antiretrovirals Promise More Effective and Better Tolerated HIV Treatment
- Details
- Category: HIV Treatment
- Published on Wednesday, 06 March 2013 00:00
- Written by Liz Highleyman
New antiretroviral drugs and treatment strategies are no longer the predominant focus of the annual Conference on Retroviruses and Opportunistic Infections (CROI), but this year's meeting included several presentations on refinements to HIV therapy that offer the prospect of greater efficacy -- especially for people with resistant virus -- fewer side effects, and more convenient administration.
Web Design and Development by